<wga class="fzpalex"></wga>

尊龙凯时 - 人生就是搏!

2021 Interim Results Announcement
Hua Medicine
Aug 19, 2021
4382

9 August 2021(星期一)

calendar.jpg

2021 Interim Results Announcement

Dear Investors and Analysts,

9 August 2021 – Hua Medicine (2552.HK) ("Hua Medicine" or the "Company") cordially invites you or your representative to attend the online webinar in relation to its 2021 interim results on 19 August 2021 (Thursday) at 3:00 PM Hong Kong Time.

During the webinar, management will review the business and financial performance in the first half of 2021 and share with you their future plans.


Details of the webinar are as follows:

 


Date:

19 August 2021 (Thursday)

Time:

Login starts: 2:45PM Hong Kong Time
Meeting starts: 3:00PM Hong Kong Time

Duration:

1 hour (including Q&A session)

Meeting Language:

English

Management:

Mr. Li Chen, Chief Executive Officer and Chief Scientific Officer
Mr. George Lin, Chief Financial Officer and Executive Vice President

RSVP:

Registration Link:
 http://icaasia.zoom.us/webinar/register/WN_AV_p5Uu3TZqxaXoixeG4UQ
(Please register via the link above by 19 August 2021)
1. Registration is open to invited participants only. All registration will be subject to management approval.
2. Upon successful registration, a personalized meeting link will be sent to the registered email. Please join the meeting via the link on the date of the meeting.

Q&A Arrangement:

If you would like to raise questions, please send your questions to huamedicine@icaasia.com from now till 19 August 2021 (Thursday).
Management will address the received questions during the Q&A session after the presentation. Subject to the meeting time, you may also raise your questions during the Q&A session.

About Hua Medicine

Hua Medicine is a leading, innovative biotechnology company in China focused on developing novel therapies for diseases with unmet medical needs. Founded by an experienced group of entrepreneurs and international investment firms, Hua Medicine advanced a first-in-class oral drug for the treatment of T2DM into NDA stage, and it has successfully completed two Phase III registration trials in China for dorzagliatin. The Company has initiated product life-cycle management studies of this novel diabetes therapy and advanced its use in personalized diabetes care. Hua Medicine is working closely with disease experts and regulatory agencies in China and across the world to advance diabetes care solutions for patients worldwide.


Focus Us
Copyright © 2024  Hua Medicine (Shanghai) Co., Ltd.    互联网药品信息服务资格证书编号: (沪)-非经营-2022-0079
沪ICP备14036654号-1  beiantubiao.png 沪公网安备 31011502013809号  Privacy Statement  Terms of Use
Search
How we use cookies
Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.
Accept
x
友情链接: